The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016:

• 40 negotiations are currently underway with 10 files added since the last update of July 31, 2016:
  • Cotellic (cobimetinib): used to treat metastatic melanoma
  • Fabrazyme (agalsidase beta): used to treat Fabry Disease
  • Fycompa (perampanel): used to treat epilepsy, primary generalized tonic-clonic seizures
  • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide): used to treat HIV-1 infection
  • Imbruvica (ibrutinib): used to treat mantle cell lymphoma
  • Jardiance (empagliflozin): used to treat diabetes mellitus, type 2 with high cardiovascular risk
  • Praluent (alirocumab): used to treat primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia
  • Repatha (evolocumab): used to treat primary hyperlipidemia and mixed dyslipidemia
  • Replagal (agalsidase alfa): used to treat Fabry Disease
  • Zytiga (abiraterone acetate): used to treat Genitourinary Metastatic Castration resistant Prostate Cancer

• 114 joint negotiations have been completed with 1 file successfully negotiated and 1 file closed since the last update of July 31, 2016:
  Completed:
  • Arnuity Ellipta (fluticasone furoate): used to treat asthma
    Closed:
  • Rosiver (ivermectin): used to treat rosacea

• 38 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of July 31, 2016.

• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of July 31, 2016.

For more information, please consult the pCPA’s website.